[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-frontotemporal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-frontotemporal":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,75,117,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100496255","cognitive-reserve-and-response-to-speech-language-intervention-in-bilingual-speakers-with-primary-progressive-aphasia-100496255",false,"NCT05741853","Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia","Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)\n* Bilingual in Spanish and Catalan or bilingual in Spanish and English\n* Different proficiency levels across languages are expected, any prior experience in both languages is acceptable\n* Intervention study: Score of 15 or higher on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of 10 or higher on the Mini-Mental State Examination\n\nExclusion Criteria:\n\n* Other central nervous system or medical diagnosis that can cause symptoms\n* Other psychiatric diagnosis that can cause symptoms\n* Significant, uncorrected visual or hearing impairment that would interfere with participation\n* Prominent initial non-speech-language impairments (cognitive, behavioral, motoric)\n* Intervention Study: Score of less than 15 on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of less than 10 on the Mini-Mental State Examination",true,"ALL","40 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.\n\nThe overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how \"strong\" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Primary Progressive Aphasia","Dementia","Dementia, Frontotemporal","Alzheimer Disease","Neurodegenerative Diseases","Frontotemporal Lobar Degeneration","Apraxia, Motor","Dysarthria","Communication Disorders","Language Disorders","Speech Disorders","Neurocognitive Disorders","Aphasia","Bilingual Aphasia",[42,43,44,27,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"Dementia, ADRD","Bilingualism","Multilingualism","Bilingual Primary Progressive Aphasia","Cognitive Reserve","Language Decline","Bilingual Language Decline","Speech-Language Therapy","Bilingual Speech-Language Therapy","Spanish speakers","Spanish-Catalan Bilinguals","Spanish-English Bilinguals","Hispanic","Catalán","Catalan","Spanish","Castellano","Speech Therapy","Latino","Cognition","RECRUITING","2026-06-08",{"date":65,"type":66},"2026-06-10","ACTUAL",{"date":68,"type":66},"2023-05-01",{"date":70,"type":21},"2027-11-30",{"name":72,"class":73},"Stephanie Grasso","OTHER",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100521076","phase-1-a-study-to-evaluate-the-safety-and-effect-of-avb-101-a-gene-therapy-product-in-subjects-with-a-genetic-sub-type-of-frontotemporal-dementia-ftd-grn-100521076","NCT06064890","A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)","A Phase 1\u002F2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)","ASPIRE-FTD","Inclusion Criteria:\n\n* Male or female, 30 to 75 years of age\n* Carriers of a pathogenic GRN mutation\n* FTD as evidenced by CDR + NACC FTLD global score of 0.5, 1.0, or 2.0\n* Presence of 1 or more of the criteria for diagnosis of possible bvFTD or PPA\n* Able and willing to comply with all procedures and the study visit schedule\n* Able and willing to give written informed consent prior to study participation, and agree to designate a legal representative to act on their wishes to continue participation should they lose capacity to consent at some point during the study OR If, in the Investigator's opinion, the subject lacks capacity to consent, written informed consent of their legal representative must be obtained in accordance with local laws, regulations, and\u002For customs. In countries where local laws, regulations, and\u002For customs do not permit subjects who lack capacity to consent to participate in this study, these subjects will not be enrolled\n* An identified, informed study partner who is able and willing to support the participant in the study and to provide assessments of the participant during the study\n\nExclusion Criteria:\n\n* Severe dementia, defined as CDR + NACC FTLD global score of 3.0, or other symptoms that preclude the ability to comply with study procedures and\u002For pose unacceptable safety risk to the subject\n* Any concurrent disease that may cause cognitive impairment unrelated to mutations in the GRN gene, such as other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin B12 deficiency\n* Clinically significant abnormality on MRI at Screening considered to be a contraindication to Intrathalamic infusion\n* Surgically significant pattern of brain atrophy on MRI at Screening that interferes with planned neurosurgical trajectory\n* Previous treatment with any gene or cell therapy\n* Previous treatment with any investigational medicinal product (IMP) within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment\n* Concomitant disease, any clinically significant laboratory abnormality, or treatment which, in the opinion of the Investigator, may pose an unacceptable safety risk to the participant or interfere with study conduct or the participant's ability to comply with study procedures including neurosurgical administration under anesthesia","30 Years","75 Years",{"count":86,"type":21},18,[88,89],"PHASE1","PHASE2","The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement. These symptoms result from below normal levels of a protein called progranulin (PGRN) in the brain, which leads to the death of nerve cells (neurons), affecting the brain's ability to function.\n\nThe main questions that the study aims to answer are:\n\n1. Is a one-time treatment with AVB-101 safe for patients with FTD-GRN?\n2. Does a one-time treatment with AVB-101 restore PGRN levels to at least normal levels?\n3. Could AVB-101 work as a treatment to slow down or stop progression of FTD-GRN?\n\nIn this study there is no placebo (a dummy pill or treatment used for comparison purposes), so all participants will receive a one-time treatment of AVB-101 delivered directly to the brain, with follow-up assessments for 5 years.",[92,93,94,29],"Frontotemporal Dementia","FTD","FTD-GRN",[96,97,98,99,100,101,27,102,103,28,104,105],"Gene Therapy","AAV","Intrathalamic","Intraparenchymal","Progranulin","Behavioral Variant FTD","PGRN","Granulin","Dementia Gene Therapy","AAV9","2026-04-07",{"date":108,"type":66},"2026-04-13",{"date":110,"type":66},"2023-08-30",{"date":112,"type":21},"2030-03-21",{"name":114,"class":115},"AviadoBio Ltd","INDUSTRY",19,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100604820","phase-2-investigator-initiated-study-for-the-safety-and-efficacy-in-frontotemporal-dementia-100604820","NCT07154485","Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia","A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Investigator-initiated Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD), and Exploratory Efficacy of Multiple Doses of NS101 in Patients With Semantic Variant Primary Progressive Aphasia (svPPA), a Subtype of Frontotemporal Dementia (FTD)","Key Inclusion Criteria:\n\n* Participants diagnosed at screening with mild to moderate frontotemporal dementia, semantic variant (svFTD), defined by a CDR® Plus NACC FTLD Sum of Boxes (SOB) score between 4.5 and 15.5.\n* Participants confirmed to be amyloid-negative based on Amyloid PET scan or CSF results within the past 36 months.\n\nKey Exclusion Criteria:\n\n* Participants with other degenerative brain diseases as determined by the investigator\n* Participants with other neurological disorders and uncontrolled acute disease","55 Years","80 Years",{"count":127,"type":21},15,[89],"The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics\u002Fpharmacodynamics (PK\u002FPD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)",[131],"Dementia Frontotemporal",[92,133,93,134,135,136],"semantic variant","sv FTD","PPA","sv PPA","NOT_YET_RECRUITING","2025-09-03",{"date":140,"type":66},"2025-09-04",{"date":142,"type":21},"2025-10-01",{"date":144,"type":21},"2028-08-01",{"name":146,"class":73},"Hee-Jin Kim",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100509323","investigating-genetic-status-in-patients-presenting-to-clinic-100509323","NCT05911932","Investigating Genetic Status in Patients Presenting to Clinic","Inclusion Criteria:\n\n* Persons presenting to the cognitive clinic with a neurodegenerative disorder (for example, AD, FTD, LBD, ALSP, and related conditions);\n* Biological family members of someone diagnosed with a neurodegenerative disorder, presenting to clinic;\n* Age 18+ years old;\n* Consenting to a blood draw.\n\nExclusion Criteria:\n\n• Persons declining \u002F unwilling \u002F not able to have a blood draw.","18 Years",{"count":155,"type":21},1000,"OBSERVATIONAL","The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown. While the contribution of some genetic mutations and polymorphisms is associated with autosomal dominant patterns of inheritance of these dementias, in many cases, the specific causative mutation in these families is not yet identified. Further, in many patients, polygenic risk is thought to give rise to pathophysiologic changes, but which specific genes affect risk are largely yet unknown. By examining genotypes in patients that present to our Cognitive Neurology and Alzheimer's Research Clinic with suspected or confirmed neurodegenerative dementia, or have a history of a familial dementia, we aim to help identify and characterize genetic mutations or polymorphisms that give rise to neurodegenerative diseases.",[29,159,160],"Alzheimer Dementia (AD)","Lewy Body Dementia (LBD)",[162],"Neurodegenerative disorders","2025-03-03",{"date":165,"type":66},"2025-03-04",{"date":167,"type":66},"2023-10-20",{"date":169,"type":21},"2043-08",{"name":171,"class":73},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",1]